Mylan has announced that the US Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) proceedings on all claims against 2 patents that cover Sanofi’s innovator insulin glargine injection, Lantus.
Mylan has announced that the US Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) proceedings on all claims against 2 patents that cover Sanofi’s innovator insulin glargine injection, Lantus. The patents being challenged, US Patents number 7,476,652 and number 7,713,930, relate to formulation. Mylan filed the petitions for IPR of these patents in June 2017.
Mylan’s New Drug Application (NDA) for a follow-on insulin glargine product, in both vial and pen dosage presentations, is currently under review by the FDA. (In the United States, insulins are currently regulated as drugs and not as biologics; hence, drug makers must submit NDAs, rather than biologics license applications, for follow-on versions of originator insulin products.) Announcement of the IPR proceedings follows an October 2017 lawsuit, filed against Mylan by Sanofi, alleging that Mylan has infringed on 18 of the patents that cover Lantus. The October suit was triggered by Mylan’s submission of its NDA.
Heather Bresch, CEO of Mylan, said in a statement, "The PTAB's decision to institute IPR proceedings against the [2] Orange Book-listed patents for Lantus is another step forward in our ongoing efforts to bring an interchangeable insulin glargine to diabetes patients as soon as possible.” She added, “There are more than 29 million people in the [United States] living with diabetes who deserve access to more affordable treatment options. As a leading producer of oral diabetes medicines, we are deeply committed to this patient community and believe bringing lower-cost alternatives…will fulfill a critical medical need."
The instituted petition for IPR proceedings could help clear the way for Mylan to launch its yet-to-be-approved insulin product as a challenger to the high-earning Lantus. Mylan estimates that total sales for Lantus and Lantus SoloSTAR (a pen presentation of Lantus) for the 12 months ending on October 31, 2017, were approximately $2.74 billion and $4.98 billion, respectively.
Already competing for the US insulin glargine market is Boehringer Ingelheim’s (BI) Basaglar, the first FDA-approved insulin glargine follow-on product. Basaglar launched in the United States in 2016 after BI concluded a lengthy litigation with Sanofi over its Lantus patents. Since its launch, competition from Basaglar has produced declines in Sanofi’s share of the insulin market; in the second quarter of 2017; Sanofi’s US sales of Lantus and Toujeo (another Sanofi insulin glargine product) slipped by 23.9%. Sanofi attributed its reduced sales to the exclusion of Lantus from commercial formularies, such as those of CVS Health and UnitedHealthcare. In addition, European sales of insulin glargine sank by 2% after to competition from approved European biosimilar insulins.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.